Dosing & Uses
Dosage Forms & Strengths
- 300mgI/mL (62%)
- 350mgI/mL (73%)
CECT of Head
- 30-60 g iodine indicated
- Oxilan 300: 100-200 mL IV
- Oxilan 350: 86-172 mL IV
- Not to exceed 200 mL
CECT of Body
- 15-60 g iodine indicated
- Oxilan 300: 50-200 mL IV
- Oxilan 350: 43-172 mL IV
- Not to exceed 200 mL
8-12 mL intra-arterially (2.4-3.6 g iodine); not to exceed 150 mL
- Oxilan 350 is indicated
- Left and right coronary arteries: 2-10 mL (0.7-3.5 g iodine)
- Left ventricle: 25-50 mL (8.75-17.5 g iodine)
Safety and efficacy not established
Black Box Warning
The reaction to intrathecal administration can be fatal
Hypersensitivity to product or components
Intrathecal administration (potentially fatal)
Caution in severe renal impairment, combined renal/hepatic disease, thyroid dysfunction, multiple myeloma, anuria, pheochromocytoma, sickle cell, CHF, severe arterial/venous disease
May cause renal failure in patients with advanced vascular disease, diabetes; should be well hydrated before/after procedure
Hypersensitivity to contrast medium, iodine
Myocardial infarctions and stroke reported with angiographic procedures
Avoid extravasation, especially in patients with severe arterial or venous disease
Inhibits blood coagulation (less than ionic contrast media in vitro)
Allergies (bronchial asthma, hay fever, food allergies)
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Not known, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Opacifies vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Vd: 7-10 L
Excretion: Urine (93.7%); bile/feces (negligible)
Half-life: 137 min (men); 102 min (women)
Protein binding: Negligible
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.